TITLE:
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

CONDITION:
Chronic Hepatitis B

INTERVENTION:
telbivudine or lamivudine

SUMMARY:

      This study is being conducted to compare the safety and effectiveness of the investigational
      medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European
      and Asian Health Authorities for the treatment of hepatitis B infection. The results for
      patients taking LdT will be compared to results for patients taking Lamivudine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 16 Years to 70 Years
Criteria:

        Inclusion Criteria:

          -  Chronic Hepatitis B, documented by Clinical history compatible with chronic HBV

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Patient is pregnant or breastfeeding

          -  Patient is co infected with hepatitis C virus (HCV), hepatitis D virus (HDV), HIV-1
             or HIV-2.

          -  Patient previously received lamivudine or an investigational anti-HBV nucleoside or
             nucleotide analog at any time

          -  Patient has received interferon or other immunomodulatory treatment for HBV infection
             in the 12 months before screening for this study

        Other protocol defined exclusion criteria may apply.
      
